KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ginkgo Bioworks Holdings (DNA) Equity Ratio (2020 - 2025)

Ginkgo Bioworks Holdings' Equity Ratio history spans 6 years, with the latest figure at 0.45 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 12.62% year-over-year to 0.45; the TTM value through Dec 2025 reached 0.45, down 12.62%, while the annual FY2025 figure was 0.45, 12.62% down from the prior year.
  • Equity Ratio reached 0.45 in Q4 2025 per DNA's latest filing, down from 0.47 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.79 in Q2 2022 to a low of 0.21 in Q2 2021.
  • Average Equity Ratio over 5 years is 0.58, with a median of 0.62 recorded in 2023.
  • Peak YoY movement for Equity Ratio: soared 282.47% in 2022, then decreased 21.86% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.76 in 2021, then fell by 9.65% to 0.68 in 2022, then dropped by 3.65% to 0.66 in 2023, then dropped by 21.09% to 0.52 in 2024, then fell by 12.62% to 0.45 in 2025.
  • Per Business Quant, the three most recent readings for DNA's Equity Ratio are 0.45 (Q4 2025), 0.47 (Q3 2025), and 0.5 (Q2 2025).